Nanoparticle-Binding Immunoglobulins Predict Variable Complement Responses in Healthy and Diseased Cohorts
Li Y, Saba L, Scheinman R, Banda N, Holers M, Monte A, Dylla L, Moghimi S, Simberg D. Nanoparticle-Binding Immunoglobulins Predict Variable Complement Responses in Healthy and Diseased Cohorts. ACS Nano 2024, 18: 28649-28658. PMID: 39395006, DOI: 10.1021/acsnano.4c05087.Peer-Reviewed Original ResearchConceptsPegylated liposomal doxorubicinComplement activationPredictive valuePlasma concentrationsC-reactive protein levelsAnti-PEG IgGTriggers proinflammatory responsesAnti-PEG IgMEfficacy of nanomedicinesPoor predictive valueAnti-PEG antibodiesLiposomal doxorubicinIron oxide nanowormsHealthy donorsHigher complement activationAcute infectionInflammatory disease conditionsChronic inflammationProinflammatory responseSystemic administrationComplement cascadeComplement factorsComplement responseIgMProtein levelsOptimized Enzyme-Linked Immunosorbent Assay for Anti-PEG Antibody Detection in Healthy Donors and Patients Treated with PEGylated Liposomal Doxorubicin
Li Y, Ettah U, Jacques S, Gaikwad H, Monte A, Dylla L, Guntupalli S, Moghimi S, Simberg D. Optimized Enzyme-Linked Immunosorbent Assay for Anti-PEG Antibody Detection in Healthy Donors and Patients Treated with PEGylated Liposomal Doxorubicin. Molecular Pharmaceutics 2024, 21: 3053-3060. PMID: 38743264, DOI: 10.1021/acs.molpharmaceut.4c00278.Peer-Reviewed Original ResearchConceptsEnzyme-linked immunosorbent assayLiposomal doxorubicinHealthy donorsPatients treated with pegylated liposomal doxorubicinEnzyme-linked immunosorbent assay signalCancer patientsAnti-PEG IgGPegylated liposomal doxorubicinImmunosorbent assayOptimized ELISAEnzyme-linked immunosorbent assay protocolsAnti-PEG antibodiesChemotherapy cyclesBetween-assay variabilityPEGylated liposomesCutoff valueAccelerated clearanceTreatment cyclesDrug delivery systemsAntibody titersComplement activationInfused drugAnti-PEGOptimized assayPatients